Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-rituximab in Relapsed/Refractory FL or MCL
NCT01678417Phase 2Unknown
- Sponsor
- Korea Cancer Center Hospital
- Start
- Jun 2012
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iodine-131-rituximab in follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by Korea Cancer Center Hospital. Status: unknown.
02
Drugs
iodine-131-rituximab
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01678417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01678417.